Hypertension
Conditions
Brief summary
This study was a single center, parallel, randomized, double blind, placebo-controlled phase Ib clinical trial to to evaluate the safety and tolerability and pharmacokinetics of SPH3127 tablet in healthy subjects by increasing multiple dosing
Detailed description
Three panels(100mg, 200mg, 400mg), each consisting of eight participants (The number of individual subjects in each group was not less than 1/3 of the total number).Participants begin to receive the first dose of SPH3127 100mg. Then Participants begin to receive the second dose of SPH3127 200mg,after the researchers confirmed that the 100mg dose group was safe and well tolerated.Then the third dose of SPH3127 400mg must wait for the result of the second dose's safety and tolerability. If the subjects during escalating dose to the biggest tolerate dose group were not well tolerated, the study must adjust the maximum dose group and fall to a low dose group to conduct another test.
Interventions
DRUGSPH3127 50mg
SPH3127 50mg
DRUGSPH3127 100mg
SPH3127 100mg
DRUGPlacebo matching to SPH3127 50mg
Placebo matching to SPH3127 50mg
DRUGPlacebo matching to SPH3127 100mg
Placebo matching to SPH3127 100mg
Sponsors
Shanghai Pharmaceuticals Holding Co., Ltd
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
1. The body mass index is 18-28kg/m2 (including the critical value), which allows the minimum weight of men to be 50kg (including the critical value) and 45kg for women (including the critical value). 2. Before the study,participant has know about the significance , potential benefits, inconveniences and potential risks of the study 3. Participant has understood the research's procedure and sign the informed consent .
Exclusion criteria
* Participant who are Pregnancy, lactating women, and planned trials begin within six months of pregnancy * Participant who has abnormal Physical examination, laboratory examination results and clinical significance (such as: liver function examination - aspartate aminotransferase (AST) and alanine aminotransferase (ALT) more than 1.5 times that of the upper limit of normal) * Participant who has a history of cardiovascular, liver, kidney, digestive tract, nervous system, blood system, familial hematologic disease, abnormal thyroid function, or mental abnormality * Participant who has drug allergy history and anaphylactic reaction * Participant who took oral contraceptive in 6 months * Participant who used any drug (including Chinese herbal medicine) within 1 week. * Participant who donated blood within 2 months * Participant who participated clinical trials of any drug in 3 months (as subjects) * Participant who has any positive result of virus serology check: human immunodeficiency virus antigen antibody (HIV Ag/Ab) and hepatitis c virus (HCV) - immunoglobulin G(IgG) antibody to IgG, hepatitis b surface antigen (HBsAg) and treponema pallidum antibody (TP) * Participant who are used to smoke, alcohol abuse, eat coffee and strong tea and drug abuse * Participant who the researchers believe that there are volunteers who are not suitable for the study
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of participants with adverse events (AEs) | Baseline to 13-16 days post last dose | to assess incidence and intensity of Adverse Events according to Common Toxicity Criteria (CTC version 4.03) associated with increasing doses of SPH3127 |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change from baseline in laboratory hematology values | Baseline to 13-16 days post last dose | to evaluate the Change from baseline in laboratory hematology values |
| Change from baseline in laboratory chemistry values | Baseline to 13-16 days post last dose | to evaluate the Change from baseline in laboratory chemistry values |
| Change from baseline in laboratory urinalysis values | Baseline to 13-16 days post last dose | to evaluate the Change from baseline in laboratory urinalysis values |
| Plasma area under curve (AUC)(0-∞) of SPH3127 | 10 minutes predose, 0.17hour, 0.33hour, 0.5hour, 0.75hour, 1hour, 1.25hour, 1.5hour, 2hour, 4hour, 6hour, 8hour, 12hour postdose at Day 1 and 7; 10 minutes predose at Day 2; 10 minutes predose, 1hour postdose at Day 5 or 6 | to evaluate Plasma AUC(0-∞) of SPH3127 |
| Maximum Plasma Concentration (Cmax) of SPH3127 | 10 minutes predose, 0.17hour, 0.33hour, 0.5hour, 0.75hour, 1hour, 1.25hour, 1.5hour, 2hour, 4hour, 6hour, 8hour, 12hour postdose at Day 1 and 7;10 minutes predose at Day 2; 10 minutes predose, 1hour postdose at Day 5 or 6 | to evaluate Plasma Cmax of SPH3127 |
| Plasma Maximum time to peak (Tmax) of SPH3127 | 10 minutes predose, 0.17hour, 0.33hour, 0.5hour, 0.75hour, 1hour, 1.25hour, 1.5hour, 2hour, 4hour, 6hour, 8hour, 12hour postdose at Day 1 and 7;10 minutes predose at Day 2; 10 minutes predose, 1hour postdose at Day 5 or 6 | to evaluate Plasma Tmax of SPH3127 |
| Apparent terminal half-life of SPH3127 | 10 minutes predose, 0.17hour, 0.33hour, 0.5hour, 0.75hour, 1hour, 1.25hour, 1.5hour, 2hour, 4hour, 6hour, 8hour, 12hour postdose at Day 1 and 7;10 minutes predose at Day 2; 10 minutes predose, 1hour postdose at Day 5 or 6 | to evaluate terminal half-life of SPH3127 |
| Change from baseline in ECG | Baseline to 13-16 days post last dose | to evaluate the Change from baseline in ECG |
Countries
China
Outcome results
None listed